The 39th Annual J.P. Morgan Healthcare Conference is going virtual this year and KPMG will be launching its annual 2021 Healthcare and Life Sciences Investment Outlook, leveraging digital and social mediums as well as hosting a series of virtual events to coincide with the Conference. Hear from leading industry luminaries, emerging fast-growth companies, innovative technology creators, and members of the investment community and gain forward-looking perspectives and insights on key life sciences and healthcare topics.
We welcome you to join us for the following events:
- January 13, 2021
- January 14, 2021
- January 25, 2021
- January 27-28, 2021
- February 2, 2021
January 13, 2021
January 13, 2021 | Vlog: 2021 Healthcare and Life Sciences Investment Outlook
Hear from KPMG healthcare and life sciences leaders as they provide their perspectives related to the 2021 Healthcare and Life Sciences Investment Outlook.
- Kristin Pothier, Principal, Global and National Healthcare & Life Sciences Deal Advisory and Strategy Leader
- Larry Kocot, Principal and National Leader, Center for Healthcare Regulatory Insight
- Brett Glover, Partner, Healthcare & Life Sciences Deal Advisory Leader
January 14, 2021
January 14, 2021 | 11:00 am ET | LinkedIn Live: Leavitt Partners Future Frame Series
2021 Investment Strategies and Growth Opportunities in Healthcare
Join Andrew Croshaw and Jennifer Colamonico of Leavitt Partners, and special guest Brett Glover, Partner and Healthcare Deal Advisor at KPMG, for a discussion on the most impactful healthcare trends for investors in 2021.
January 25, 2021
January 25, 2021 | Launch: 2021 Healthcare and Life Sciences Investment Outlook
The KPMG 2021 Healthcare and Life Sciences Investment Outlook paper sheds light on the investment landscape, influential disruptors, evolving market trends, and policy/regulatory developments.
January 27-28, 2021
January 27-28, 2021 | Goodwin + KPMG @ JPMorgan Symposium
Our 2nd Annual Goodwin + KPMG @ JPMorgan Symposium will be a virtual event spanning two half days devoted to accelerated innovation in the life sciences industry galvanized exponentially because of the global COVID-19 pandemic.
Attend the Symposium and gain new insights and fresh perspectives on:
- What will 2021 and beyond look like in this new reality?
- Looking forward, how is accelerated innovation in the industry a silver lining?
- Who and what are the catalysts for change, and why?
- What is the future of deal-making and how will deals get done?
Wednesday, January 27, 2021 | 12:30 pm - 4:00 pm EST
The COVID Catalyst
- 12:30 pm – 12:35 pm | Opening Remarks
- 12:40 pm – 1:25 pm | Fireside Chat with Noubar Afeyan, Co-Founder and CEO of Flagship Pioneering and Co-Founder of Moderna
Stuart Cable, Vice Chairman, Global Chair of M+A and Partner, Goodwin (Moderator)
- 1:30 pm – 2:15 pm | The COVID Catalyst: Driving Innovation Mainstream
Life sciences as a sector is always innovating, but COVID-19 has forced us to turbo-boost innovation across the continuum – whether it be devices, therapeutics, diagnostics, supply chain, the dissemination of needed products and services on a worldwide scale, or the fundamental delivery of care – finding ways to improve has never been more important. This acceleration was apparent for COVID and non-COVID products and services. Hear from leaders across this continuum on what needed to be done and what their expectations are for continued acceleration moving forward.
- 2:20 pm – 3:05 pm | COVID Gives Digital Health A Shot In The Arm
Digital health and data have come to the forefront with an emphasis on increased demand for virtual care. How have we forecasted it and how do we forecast it moving forward? Who is doing it and who are the major players? We will also discuss the continued quest for data to fuel holistic solutions.
- 3:10 pm – 3:55 pm | How Will the 2020 SPACs Revolution Impact the IPO Market for 2021 and Beyond
In light of 2020’s market volatility, business combinations with SPACs, or SIPOs, have become increasingly popular financing transactions utilized by companies across industries as a means of raising capital and accessing the public markets. What impact, if any, will the SPAC revolution have on the IPO market for 2021?
Thursday, January 28, 2021 | 11:00 am - 12:30 pm; 3:30 pm - 4:10 pm EST
COVID Effects on the Life Sciences Industry
- 11:00 am – 11:40 am | What Innovation in the Biopharma Market Will Look Like in the Post-COVID Era
The biopharma market is booming and experts predict it will continue to grow exponentially over the next four years. What is predicating this growth? Is it just the recent COVID-19 pandemic or is the pandemic just the impetus for the recent growth?
- 11:45 am – 12:30 pm | Global Life Sciences Outlook 2021
The pandemic has triggered numerous and lasting changes in the life sciences ecosystem, putting more of a focus on the global supply chain than in previous years. Where will the growth in the life sciences industry come from in 2021 and beyond? We will discuss growth in the U.S. versus globally; internal scaling or partnerships and M&A opportunities; and whether Europe will continue to be a focus for 2021 and beyond.
- 3:30 pm – 4:10 pm | Fireside Chat with Carl Hansen, CEO of AbCellera: Drug Discovery and Accelerated Adoption of AI and Machine Learning in our New Reality
Deepa Rich, Partner, Goodwin (Moderator)
2020 Goodwin + KPMG @ JPMorgan Symposium Highlights
On Wednesday, January 15, 2020, during the J.P. Morgan Healthcare conference, Goodwin and KPMG held their initial all-day Symposium at the St. Regis hotel in San Francisco. The Symposium was composed of five separate bursts/sessions: (i) New Frontiers in Digital Diagnostics and MedTech, (ii) Europe Unleashed, (iii) Knowing the Best IPO Strategy, (iv) Trends in Biopharma and (v) Mergers and Acquisitions. Stéphane Bancel, the Chief Executive Officer of Moderna Therapeutics, provided the keynote address.
February 2, 2021
February 2, 2021 | 12:00 pm - 1:00 pm ET | Insights from the 2021 Healthcare and Life Sciences Investment Outlook
Larry Kocot, Principal and National Leader, Center for Healthcare Regulatory Insight and Steve Sapletal, Principal, Healthcare and Life Sciences Deal Advisory & Strategy Leader will co-chair a virtual event joined by Kristin Pothier, Principal, Global and National Healthcare & Life Sciences Deal Advisory and Strategy Leader, Brett Glover, Partner, Healthcare & Life Sciences Deal Advisory Leader, Jeff Stoll, Principal, National Life Sciences Strategy Leader, and Ross Nelson, M.D. Principal, National Healthcare Strategy Leader will share perspectives on primary market insights and survey data, as well as share salient points from the recently launched KPMG 2021 Healthcare and Life Sciences Investment Outlook, followed by a question and answer session.